GRIT Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
200
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$84.3M
- Investors
-
26
GRIT Therapeutics General Information
Description
Developer of cell and gene therapies designed to advance treatment options for cancer and autoimmune diseases through engineered T-cell technologies. The company offers in vivo CAR-T platforms, tumour-infiltrating lymphocyte therapies, gene-editing capabilities, and targeted delivery technologies, enabling healthcare providers and patients with complex immune-related diseases to access scalable and precision-driven immunotherapies.
Contact Information
Website
www.grit-bio.comCorporate Office
- Building 20, Number 156, Jinghai Fourth Road, Boxing Street
- Daxing District
- Beijing, 518055
- China
Corporate Office
- Building 20, Number 156, Jinghai Fourth Road, Boxing Street
- Daxing District
- Beijing, 518055
- China
GRIT Therapeutics Timeline
GRIT Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series C) | 09-Oct-2025 | $84.3M | Completed | Generating Revenue | ||
| 8. Later Stage VC (Series B2) | 29-Jul-2025 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B1) | 29-Dec-2024 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 25-Oct-2023 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B) | 15-Aug-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A1) | 15-Jul-2021 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Private | 16-Mar-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 10-Dec-2020 | $15.2M | $15.2M | Completed | Generating Revenue | |
| 1. Seed Round | 23-Aug-2020 | Completed | Startup |
GRIT Therapeutics Comparisons
Industry
Financing
Details
GRIT Therapeutics Competitors (47)
One of GRIT Therapeutics’s 47 competitors is CureGenetics, a Venture Capital-Backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CureGenetics | Venture Capital-Backed | Suzhou, China | ||||
| IASO Biotechnology | Venture Capital-Backed | Nanjing, China | ||||
| Commense Bio | Venture Capital-Backed | Boulder, CO | ||||
| FosunKairos | Venture Capital-Backed | Shanghai, China | ||||
| Mabworks Biotech | Venture Capital-Backed | Beijing, China |
GRIT Therapeutics Patents
GRIT Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023197980-A1 | Chimeric antigen receptor and use thereof | Inactive | 11-Apr-2022 | ||
| US-20250127895-A1 | Modified tumor infiltrating lymphocyte and use thereof | Pending | 29-Jan-2022 | ||
| WO-2023143515-A1 | Modified tumor infiltrating lymphocyte and use thereof | Inactive | 29-Jan-2022 | ||
| WO-2023138598-A1 | Use of tumor-infiltrating lymphocyte in treatment of diseases | Inactive | 19-Jan-2022 | ||
| WO-2023125772-A1 | Modified tumor-infiltrating lymphocyte and use thereof | Inactive | 30-Dec-2021 |
GRIT Therapeutics Signals
GRIT Therapeutics Investors (26)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Jiangsu Huarui Investment | PE/Buyout | Minority | ||
| Yantai Finance and Investment Development Group | Government | Minority | ||
| Yizhuang Holdings | Asset Manager | Minority | ||
| Beijing Shunxi Private Equity Fund Management | Growth/Expansion | Minority | ||
| Beijing Zhongguancun Capital Fund Management | Growth/Expansion | Minority |
GRIT Therapeutics FAQs
-
When was GRIT Therapeutics founded?
GRIT Therapeutics was founded in 2019.
-
Where is GRIT Therapeutics headquartered?
GRIT Therapeutics is headquartered in Beijing, China.
-
What is the size of GRIT Therapeutics?
GRIT Therapeutics has 200 total employees.
-
What industry is GRIT Therapeutics in?
GRIT Therapeutics’s primary industry is Drug Discovery.
-
Is GRIT Therapeutics a private or public company?
GRIT Therapeutics is a Private company.
-
What is GRIT Therapeutics’s current revenue?
The current revenue for GRIT Therapeutics is .
-
How much funding has GRIT Therapeutics raised over time?
GRIT Therapeutics has raised $208M.
-
Who are GRIT Therapeutics’s investors?
Jiangsu Huarui Investment, Yantai Finance and Investment Development Group, Yizhuang Holdings, Beijing Shunxi Private Equity Fund Management, and Beijing Zhongguancun Capital Fund Management are 5 of 26 investors who have invested in GRIT Therapeutics.
-
Who are GRIT Therapeutics’s competitors?
CureGenetics, IASO Biotechnology, Commense Bio, FosunKairos, and Mabworks Biotech are some of the 47 competitors of GRIT Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process